Literatura científica selecionada sobre o tema "MitoTALEN"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "MitoTALEN".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "MitoTALEN"
Omukai, Shiho, Shin-ich Arimura, Kinya Toriyama e Tomohiko Kazama. "Disruption of mitochondrial open reading frame 352 partially restores pollen development in cytoplasmic male sterile rice". Plant Physiology 187, n.º 1 (20 de maio de 2021): 236–46. http://dx.doi.org/10.1093/plphys/kiab236.
Texto completo da fonteHashimoto, Masami, Sandra R. Bacman, Susana Peralta, Marni J. Falk, Anne Chomyn, David C. Chan, Sion L. Williams e Carlos T. Moraes. "MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases". Molecular Therapy 23, n.º 10 (outubro de 2015): 1592–99. http://dx.doi.org/10.1038/mt.2015.126.
Texto completo da fonteBacman, Sandra R., Johanna H. K. Kauppila, Claudia V. Pereira, Nadee Nissanka, Maria Miranda, Milena Pinto, Sion L. Williams, Nils-Göran Larsson, James B. Stewart e Carlos T. Moraes. "MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation". Nature Medicine 24, n.º 11 (24 de setembro de 2018): 1696–700. http://dx.doi.org/10.1038/s41591-018-0166-8.
Texto completo da fonteBacman, Sandra R., Johanna H. K. Kauppila, Claudia V. Pereira, Nadee Nissanka, Maria Miranda, Milena Pinto, Sion L. Williams, Nils-Göran Larsson, James B. Stewart e Carlos T. Moraes. "Author Correction: MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation". Nature Medicine 24, n.º 12 (5 de outubro de 2018): 1940. http://dx.doi.org/10.1038/s41591-018-0234-0.
Texto completo da fonteYashina, D. P., e Z. A. Afanasieva. "Experience of mitotane successful in the treatment of metastatic adrenocortical cancer". Endocrine Surgery 15, n.º 4 (14 de dezembro de 2022): 12–13. http://dx.doi.org/10.14341/serg12764.
Texto completo da fonteSava, Alexandra Daniela, Tiberiu Bogdan Szekely, Cornelia Togănel, Adela Vacar e Simona Gurzu. "Adrenocortical carcinoma: A tumor with poor answer to classic chemotherapy". Acta Marisiensis - Seria Medica 69, n.º 4 (1 de dezembro de 2023): 292–94. http://dx.doi.org/10.2478/amma-2023-0039.
Texto completo da fonte&NA;. "Mitotane". Reactions Weekly &NA;, n.º 1385 (janeiro de 2012): 33. http://dx.doi.org/10.2165/00128415-201213850-00121.
Texto completo da fonte&NA;. "Mitotane". Reactions Weekly &NA;, n.º 1180 (dezembro de 2007): 28. http://dx.doi.org/10.2165/00128415-200711800-00084.
Texto completo da fonte&NA;. "Mitotane". Reactions Weekly &NA;, n.º 1155 (junho de 2007): 14. http://dx.doi.org/10.2165/00128415-200711550-00039.
Texto completo da fonte&NA;. "Mitotane". Reactions Weekly &NA;, n.º 1399 (abril de 2012): 23. http://dx.doi.org/10.2165/00128415-201213990-00084.
Texto completo da fonteTeses / dissertações sobre o assunto "MitoTALEN"
Kubilinskas, Rokas. "MitoTALENs to explore mitochondrial DNA repair and segregation". Electronic Thesis or Diss., Strasbourg, 2024. http://www.theses.fr/2024STRAJ014.
Texto completo da fonteFor long, the plant mitochondrial genome (mtDNA) was not amenable to manipulation, until recent advancements in genome engineering using Transcription Activator-Like Effector Nucleases (TALEN). In this work I used TALENs specifically targeted to mitochondria (mitoTALENs) to study plant mtDNA repair and segregation. MitoTALEN constructs were transformed into the background of 10 different Arabidopsis thaliana mutant lines, deficient in various factors involved in plant mitochondrial repair by homologous recombination. The resulting lines were analysed by Illumina sequencing and qPCR approaches. In wild type plants, the mtDNA double-strand-break (DSB) induced by MitoTALENs was repaired by homologous recombination, resulting in the replacement of the region containing the DSB by a distal unaffected sequence of the mtDNA, flanked by the same set of repeated sequences. In mutants deficient in repair factors, repair could shift to alternative pathways, such as Single-Strand Annealing (SSA) and Microhomology-mediated recombination (MHMR). Furthermore, in some mutants, the data revealed no evidence of DSB repair, but rather suggested that plants deficient in key repair factors could survive by reconstituting an alternative viable mitochondrial genome, from pre-existing autonomously replicating sub-genomes
Hescot, Ségolène. "Cibles moléculaires du Mitotane : Implications pour le traitement du corticosurrénalome". Thesis, Paris 11, 2015. http://www.theses.fr/2015PA11T040.
Texto completo da fonteMitotane is o,p’DDD, an historic drug derived from an insecticide and represents the treatment of choice for adrenocortical carcinoma (ACC), a rare adrenal tumor associated with bad prognosis. Mitotane is responsible for an inhibition of steroidogenesis associated with an antitumoral effect but its exact molecular mechanisms of action remain unclear and its molecular target remains unknown. However, mitochondria could be an organite targeted by mitotane. In this study we evaluated mitochondrial impact of mitotane using complementary approaches on several experimental models. We showed a mitotane-induced selective inhibition of respiratory chain complexes I and IV, an increased fission of the mitochondrial network and an activation of the mitochondrial biogenesis. These data helped us to identify mitochondrial-associated membranes (MAM) and so-called transduceosome as targeted organites of mitotane. We also reevaluated the potential role of the acid metabolite o,p’DDA and excluded its implication in the cytotoxic action of mitotane. Finally, we demonstrated that free mitotane which is not linked to lipoproteins is more efficient in vitro and could be therefore responsible for pharmacological action in vivo. Altogether, these results allow to better understand mitotane mechanisms of action and should help to identify predictive markers of response to mitotane for a better care of patients with ACC
GENTILIN, Erica. "Studio dell’azione del Mitotane, farmaco adrenolitico, sulla funzionalità ipofisaria". Doctoral thesis, Università degli studi di Ferrara, 2011. http://hdl.handle.net/11392/2388826.
Texto completo da fonteAttivi, David. "Mise en forme et amélioration de la biodisponibilité d'un anticancéreux destiné à la voie orale : exemple du mitotane". Thesis, Nancy 1, 2010. http://www.theses.fr/2010NAN10022/document.
Texto completo da fonteMitotane or o, p'-DDD is a organochlorine drug, very slightly soluble in water. It is used in the treatment of non resectable and metastasized adrenocortical carcinoma (Lysodren®). In therapy, to achieve therapeutic plasma level, high cumulative doses of mitotane were usually used during 3-5 months. This regimen causes gastrointestinal and neuromuscular side effects and make patients to be less compliants.The main objective of this work is to developp differents formulations of mitotane in order to improve the relative bioavailability when compared with conventional form Lysodren®. To shorten this equilibration time and reduce side effects, it's necessary to develop a new formulation. In order to increase mitotane solubility and make it more bioavailable, we encapsulated mitotane in polymeric particles and microemulsions.We prepared nanocapsules with biodegradable polymers (poly-epsilon-caprolactone) (PCL) and an association of PCL and non-biodegradable polymers (Eudragit®RL). We have also prepared PCL microparticles and a Self Microemulsifying Drug Delivery System or SMEDDS.Nanocapsules and microparticles diameters were respectively 300 nm and 40 to 76 µm. The zeta potential is negative for PCL particles wheras particles combining PCL and Eudragit®RL polymers exhibited positive zêta potential. For microemulsions, we investigated by constructing ternary phase diagrams and choosing the optimal formulation consisted of a mixture of Capryol®, Tween® 20 and Cremophor® EL (33, 33, 33%) with an emulsion diameter of 40 nm. The release of mitotane from SMEDDS and particles was higher and faster than from the conventional form Lysodren®.Pharmacokinetics after single-dose of oral mitotane formulations (100 mg/kg) in rabbits showed a 339% increase of relative bioavailability with microemulsions, 195% with the nanocapsules and 187% with the microparticles. Caco-2 cell culture showed a complete absorption of mitotane after 4h with microemulsions. For microparticles and nanocapsules, 50 and 45% of the initial dose, were respectively absorbed by Caco-2 cells. Caco-2 cells evaluation confirmed the low absorption of the mitotane powder (10%). Finally, Ussing chamber showed that microemulsions pass through the intestinal barrier 5 times higher than a solution of mitotane. In conclusion, microemulsions showed improvement of bioavailability of mitotane by a factor 3 in rabbits and could allow cost effective production. Microemulsions are a real alternative to Lysodren® which is currently available on the European market
Jacobi, Janin Melanie Katharina [Verfasser], e Florian [Akademischer Betreuer] Lang. "Zelltod humaner Erythrozyten durch Mitotan und Miltefosin / Janin Melanie Katharina Jacobi ; Betreuer: Florian Lang". Tübingen : Universitätsbibliothek Tübingen, 2018. http://d-nb.info/1196704031/34.
Texto completo da fonteBENSAID, JEAN-JACQUES. "Insuffisance surrenale definitive induite par op'ddd dans le syndrome de cushing : a propos de 4 observations". Lille 2, 1992. http://www.theses.fr/1992LIL2M256.
Texto completo da fonteWiemer, Laura Elisa [Verfasser], Martin [Gutachter] Fassnacht e Andreas [Gutachter] Rosenwald. "In-vitro-Untersuchungen zur molekularen Wirkung von Mitotane beim Nebennierenrindenkarzinom / Laura Elisa Wiemer. Gutachter: Martin Fassnacht ; Andreas Rosenwald". Würzburg : Universität Würzburg, 2013. http://d-nb.info/1102823414/34.
Texto completo da fonteSantos, Inês Carreira dos. "Clínica e cirurgia de animais de companhia". Master's thesis, Universidade de Évora, 2018. http://hdl.handle.net/10174/23096.
Texto completo da fonteDias, Raquel Macedo. "Separação cromatografica quiral do o,p'-diclorodifenildicloroetano (mitotano) em fase estacionaria quiral O,O'bis[4-terc-butilbenzoil]-N,N'dialil-L-tartadiamida". [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/266169.
Texto completo da fonteDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Engenharia Quimica
Made available in DSpace on 2018-08-08T16:18:50Z (GMT). No. of bitstreams: 1 Dias_RaquelMacedo_M.pdf: 1158217 bytes, checksum: 17fc0268f6869b95e17b301e65d69e9c (MD5) Previous issue date: 2007
Resumo: O mitotano (o,p?-diclorodifenildicloroetano) é um fármaco utilizado no tratamento de carcinoma adrenocortical. Ele é comercializado na forma racêmica, ou seja, na proporção 1:1 dos seus enantiômeros R e S. A influência da quiralidade da molécula sobre seu efeito farmacológico ainda não foi estudada. Portanto, a separação dos enantiômeros é importante para testes biológicos comparativos de efeitos colaterais. Este trabalho foi desenvolvido com o intuito de estudar a separação deste fármaco pela técnica de cromatografia líquida de alta eficiência utilizando coluna recheada com a fase estacionária quiral O,O?-bis[4-tercbutilbenzoil]-N,N?-dialil-L-tartardiamida. Diferentes combinações de fase móvel foram testadas e os melhores resultados foram obtidos com hexano/acetato de etila na proporção 95/5 (v/v). Experimentos de pulsos com soluções diluídas do traçador e dos enantiômeros do mitotano foram realizados variando a vazão de fase móvel e a temperatura do sistema. Foram determinados as porosidades do sistema, os parâmetros cromatográficos, os dados de equilíbrio, coeficientes de dispersão axial e parâmetros de transferência de massa. Os resultados mostraram separação satisfatória, com número de pratos superando 9000 e fatores de separação na ordem de 1,13. Os valores dos coeficientes de Henry foram maiores que a unidade para ambos os enantiômeros, sendo que o enantiômero mais retido R-(+)-mitotano, apresentou maior afinidade pela coluna quiral. Valores de km superiores a 300 min-1 revelaram baixo efeito dos fenômenos de transferência de massa e consequentemente predomínio dos efeitos termodinâmicos (energia entálpica superior -10 kJ/mol para os enantiômeros). Experimentos a altas concentrações foram realizados com a finalidade de se determinar às isotermas pelo método da análise frontal e também os cromatogramas sob estas condições. Para a concentração da mistura até 16 g/L as isotermas mostraram um bom ajuste ao modelo de Langmuir. A partir da separação em batelada determinaram-se as regiões de separação dos enantiômeros para um sistema cromatográfico contínuo do tipo leito móvel simulado para diferentes concentrações de alimentação da mistura racêmica. Avaliaram-se as variáveis desempenho (consumo de solvente e produtividade) no sistema contínuo e compararam-se com as obtidas em separações em batelada. Melhores resultados foram obtidos para um sistema contínuo do tipo leito móvel simulado
Abstract: Mitotane (o, p'-dichlorodiphenyldichloroethane) is a drug used in the treatment of adrenocortical carcinoma. It is marketed in the racemic form, proportion 1:1 of their R and S enantiomers. The influence of the molecule quirality on its pharmacology effect was not studied yet. For this reason, this separation is important for comparative biological tests of collateral effects. This work was developed with intention to study the separation of this drug via liquid chromatography using columns packed with the chiral stationary phase, O,O?-bis[4-terc-butylbenzoyl] - N, N' - diallyl-L-tartardiamide. Different combinations of mobile phase was tested and better results were achieved with hexane/ethyl acetate in ratio 95/5 (v/v). Pulses experiments with diluted solutions of the inert and the enantiomers were accomplished at different flow rates and temperature. The system porosities, chromatographic parameters, equilibrium constants, axial dispersion and mass transference parameters were obtained. The results showed satisfactory separation, with number of plates overcoming 9000 and separation factors in the order of 1,13. The values of Henry coefficients were greater than one for both enantiomers, the most retained was R (+) -mitotane, and it presented greater affinity for the chiral column. The overall mass transfer coefficient achieved values higher than 300 min-1, demonstrating low mass transfer effect rates and consequently a prevalence of the thermodynamic effects (enthalpy energy greater than -10 kJ/mol for the enantiomers). Experiments in overload conditions were realized in order to determining the isotherms using the method of the frontal analysis as well the chromatograms under these conditions. For the concentration of the mixture smaller than 16 g/L the isotherms showed a good adjusted to the Langmuir model. The separation regions for a chromatographic continuous system like simulated moving bed were determined with different feed concentrations. This permits the comparison of the performance parameters using the continuous system and batch ones
Mestrado
Desenvolvimento de Processos Biotecnologicos
Mestre em Engenharia Química
Asp, Vendela. "In Vitro Studies of Adrenocorticolytic DDT Metabolites, with Special Focus on 3-methylsulfonyl-DDE". Doctoral thesis, Uppsala universitet, Ekotoxikologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-122721.
Texto completo da fonteLivros sobre o assunto "MitoTALEN"
Ball, Steve, e Sajid Kalathil. Adrenocortical cancer. Editado por James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0094.
Texto completo da fonteHugo, Aurélien Brackers de. Evaluation du Risque Ecotoxicologique des résidus médicamenteux: Le cas du Mitotane aux Hospices Civils de Lyon. Omniscriptum, 2012.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "MitoTALEN"
Terzolo, Massimo, Arianna Ardito, Barbara Zaggia, Silvia De Francia e Fulvia Daffara. "Mitotane". In Adrenocortical Carcinoma, 369–81. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-77236-3_22.
Texto completo da fonteDe Francia, Silvia, Paola Perotti, Vittoria Basile, Antonina Germano e Massimo Terzolo. "Adrenal Cortical Carcinoma: Mitotane and Beyond". In Contemporary Endocrinology, 311–30. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-62470-9_13.
Texto completo da fonteArimura, Shin-ichi. "MitoTALENs: A Method for Targeted Gene Disruption in Plant Mitochondrial Genomes". In Methods in Molecular Biology, 335–40. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1653-6_22.
Texto completo da fonteKazama, Tomohiko, e Shin-ichi Arimura. "A Method for Precisely Identifying Modifications to Plant Mitochondrial Genomes by mitoTALENs". In Methods in Molecular Biology, 365–78. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2922-2_25.
Texto completo da fonte"Mitotane". In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2362–63. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/01044-5.
Texto completo da fontePapich, Mark G. "Mitotane". In Saunders Handbook of Veterinary Drugs, 538–40. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00398-3.
Texto completo da fonte"Mitotane". In Meyler's Side Effects of Drugs, 1071. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01094-5.
Texto completo da fonte"Mitotane." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1148.
Texto completo da fonteFurman, Brian L. "Mitotane". In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62198-1.
Texto completo da fonteFurman, B. L. "Mitotane ☆". In Reference Module in Biomedical Sciences. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-801238-3.98010-3.
Texto completo da fonteTrabalhos de conferências sobre o assunto "MitoTALEN"
Santana, Amanda S., Felipe R. Sampaio e Carlos Roque D. Correia. "Synthesis of New Mitotane Analogues". In 15th Brazilian Meeting on Organic Synthesis. São Paulo: Editora Edgard Blücher, 2013. http://dx.doi.org/10.5151/chempro-15bmos-bmos2013_2013914141646.
Texto completo da fonteHerry, H., A. Schmouchkovitch, P. Thuillier, V. Kerlan, G. Le Toux e S. Boisramé. "Lichen plan buccal induit par Mitotane : à propos d’un cas". In 64ème Congrès de la SFCO, editado por S. Boisramé, S. Cousty, J. C. Deschaumes, V. Descroix, L. Devoize, P. Lesclous, C. Mauprivez e T. Fortin. Les Ulis, France: EDP Sciences, 2016. http://dx.doi.org/10.1051/sfco/20166403024.
Texto completo da fonteGarg, Madhu B., Jennette A. Sakoff e Stephen P. Ackland. "Abstract 1671: A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients". In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1671.
Texto completo da fonte